Qiagen stock: JPMorgan lifts target for Qiagen stock to USD 55.00

Published on 10/19/2026 at 15:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 535.04 million versus USD 527.50 million. Qiagen stock costs EUR 41.14 on October 19, 2026, plus 0.27 percent versus Xetra close.

Analyst target and reporting date

JPMorgan set a USD 55.00 target on October 14, 2026, up from USD 50.00 with 20.77 percent indicated upside.
Qiagen reported USD 535.04 million in second-quarter revenue against USD 527.50 million estimates.
Qiagen stock costs EUR 41.14 at Lang & Schwarz on October 19, 2026 at 3:08 p.m. CEST, plus 0.27 percent above the Xetra close of October 16, 2026.
Qiagen trades at a P/E ratio of 23.66 with a USD 9.5 billion market capitalization.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

JPMorgan Chase raised its Qiagen price target from USD 50.00 to USD 55.00 on October 14, 2026, while maintaining an Overweight rating. MarketBeat said the target represented 20.77 percent upside from the reported USD 45.54 price. Qiagen stock was trading at EUR 41.14 at Lang & Schwarz on October 19, 2026 at 3:08 p.m. CEST, plus 0.27 percent versus the Xetra close of October 16, 2026 at EUR 41.03.

Second-quarter revenue versus estimates

Qiagen reported USD 535.04 million in second-quarter revenue, compared with USD 527.50 million in estimates, according to MarketBeat. The same report placed quarterly earnings per share at USD 0.62 against a USD 0.60 consensus, but the revenue comparison is the clearer operating marker for the next report.

Price position below the yearly high

The US-listed QGEN quote was last at USD 46.13 on October 16, 2026 at 4:00 p.m. ET. Its 52-week range was USD 32.53 to USD 57.82, leaving the share 20.22 percent below the high on that date. The euro quote and the home-market quote describe different venues, so the comparison is kept separate.

Valuation and reporting date

Qiagen had a P/E ratio of 23.66 and a market capitalization of USD 9.5 billion as of October 16, 2026. MarketBeat lists November 3, 2026 as the estimated third-quarter reporting date, after the market closes, with the conference call scheduled for November 4, 2026 at 9:30 a.m. ET.

Comparison with peers

Qiagen: plus 0.27 percent, P/E 23.66, market capitalization USD 9.5 billion
Thermo Fisher Scientific (NYSE, USD): minus 0.93 percent, P/E 37.12, market capitalization USD 255.1 billion
Danaher (NYSE, USD): minus 1.06 percent, P/E 40.68, market capitalization USD 161.0 billion

Trading level and next date

The next scheduled reporting date gives the market a defined calendar point after the October 14 target increase. Qiagen's current euro quote remains 20.22 percent below the USD 57.82 yearly high when the home-market range is measured in its own currency. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.